Physician profile
Grace Fitzpatrick
NPI 1245782010
$11,646.42
in general payments reported to CMS, 2019-2025
48 companies · $2,461 in 2025
The $2,461 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,334 · 2022: $2,576 · 2023: $2,471 · 2024: $2,804 · 2025: $2,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,658 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,658.47 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,411.97 | 2021-2025 | |
| Janssen Biotech, INC. | $1,127.33 | 2022-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,000.05 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $665.12 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $590.90 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $516.77 | 2022-2025 | Dupixent |
| Genzyme Corporation | $494.05 | 2021-2025 | |
| Ardelyx, INC. | $405.47 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $387.77 | 2022-2025 | Ocaliva |
| Amgen INC. | $371.85 | 2021-2023 | Amjevita, Avsola |
| Gilead Sciences, INC. | $255.15 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.54 | 2021-2023 | Cyltezo |
| Qol Medical, LLC | $223.59 | 2022-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $205.99 | 2021-2024 | Dificid, Zinplava |
| Madrigal Pharmaceuticals | $199.84 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.